Literature DB >> 1544168

N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production.

P Peristeris1, B D Clark, S Gatti, R Faggioni, A Mantovani, M Mengozzi, S F Orencole, M Sironi, P Ghezzi.   

Abstract

TNF is a major mediator in the pathogenesis of endotoxic shock, and its inhibition has a protective effect in various animal models of sepsis or endotoxin (lipopolysaccharide, LPS) toxicity. LPS treatment also induces an oxidative damage mediated by increased production of reactive oxygen intermediates. N-Acetylcysteine (NAC) is an antioxidant and a precursor of the synthesis of glutathione (GSH) and was reported to protect against LPS toxicity and LPS-induced pulmonary edema. In this study we investigated the effect of NAC on TNF production and LPS lethality in mice. The results indicated that oral administration of NAC protects against LPS toxicity and inhibits the increase in serum TNF levels in LPS-treated mice. The inhibition was not confined to the released form of TNF, since NAC also inhibited LPS-induced spleen-associated TNF. On the other hand, the inhibitor of GSH synthesis, DL-buthionine-(SR)-sulfoximine (BSO), had the opposite effect of potentiating LPS-induced TNF production, and this was associated with a decrease in liver GSH levels. Repletion of liver GSH with NAC reversed this effect. NAC was also active in inhibiting TNF production and hepatotoxicity in mice treated with LPS in association with a sensitizing dose of Actinomycin D. These data indicate that GSH can be an endogenous modulator of TNF production in vivo. On the other hand, NAC pretreatment did not inhibit other effects of LPS, particularly induction of serum IL-6, spleen IL-1 alpha, and corticosterone, in the same experimental model, suggesting that the observed effect could be specific for TNF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544168     DOI: 10.1016/0008-8749(92)90205-4

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  36 in total

Review 1.  The glutathione system: a new drug target in neuroimmune disorders.

Authors:  Gerwyn Morris; George Anderson; Olivia Dean; Michael Berk; Piotr Galecki; Marta Martin-Subero; Michael Maes
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

2.  Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine.

Authors:  M Sagara; J Satoh; R Wada; S Yagihashi; K Takahashi; M Fukuzawa; G Muto; Y Muto; T Toyota
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

3.  The effect of N-acetylcysteine on total serum anti-oxidant potential and urinary albumin excretion in critically ill patients.

Authors:  Z Molnar; K L MacKinnon; E Shearer; D Lowe; I D Watson
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

4.  Prophylactic N-acetylcysteine decreases serum CRP but not PCT levels and microalbuminuria following major abdominal surgery. A prospective, randomised, double-blinded, placebo-controlled clinical trial.

Authors:  Zsolt Molnar; Tamas Szakmany; Tamas Koszegi
Journal:  Intensive Care Med       Date:  2003-04-08       Impact factor: 17.440

5.  Depletion of hepatic glutathione prevents death receptor-dependent apoptotic and necrotic liver injury in mice.

Authors:  H Hentze; F Gantner; S A Kolb; A Wendel
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  IFN-ε protects primary macrophages against HIV infection.

Authors:  Carley Tasker; Selvakumar Subbian; Pan Gao; Jennifer Couret; Carly Levine; Saleena Ghanny; Patricia Soteropoulos; Xilin Zhao; Nathaniel Landau; Wuyuan Lu; Theresa L Chang
Journal:  JCI Insight       Date:  2016-12-08

7.  Effect of bone marrow-derived mesenchymal stem cells on endotoxin-induced oxidation of plasma cysteine and glutathione in mice.

Authors:  Smita S Iyer; Edilson Torres-Gonzalez; David C Neujahr; Mike Kwon; Kenneth L Brigham; Dean P Jones; Ana L Mora; Mauricio Rojas
Journal:  Stem Cells Int       Date:  2010-03-08       Impact factor: 5.443

8.  Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial.

Authors:  Robert H Squires; Anil Dhawan; Estella Alonso; Michael R Narkewicz; Benjamin L Shneider; Norberto Rodriguez-Baez; Dominic Dell Olio; Saul Karpen; John Bucuvalas; Steven Lobritto; Elizabeth Rand; Philip Rosenthal; Simon Horslen; Vicky Ng; Girish Subbarao; Nanda Kerkar; David Rudnick; M James Lopez; Kathleen Schwarz; Rene Romero; Scott Elisofon; Edward Doo; Patricia R Robuck; Sharon Lawlor; Steven H Belle
Journal:  Hepatology       Date:  2013-02-04       Impact factor: 17.425

9.  Mechanisms of endotoxin-induced haem oxygenase mRNA accumulation in mouse liver: synergism by glutathione depletion and protection by N-acetylcysteine.

Authors:  M Rizzardini; M Carelli; M R Cabello Porras; L Cantoni
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

10.  Influence of N-acetylcysteine treatment on endotoxin-induced microcirculatory disturbances.

Authors:  W Schmidt; A Walther; M M Gebhard; E Martin; H Schmidt
Journal:  Intensive Care Med       Date:  1998-09       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.